Adaptive Bio (ADPT) Revenue & Revenue Breakdown
Adaptive Bio Revenue Highlights
Latest Revenue (Y)
$178.96M
Latest Revenue (Q)
$58.88M
Main Segment (Y)
Sequencing Revenue
Adaptive Bio Revenue by Period
Adaptive Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $178.96M | 5.10% |
| 2023-12-31 | $170.28M | -8.11% |
| 2022-12-31 | $185.31M | 20.06% |
| 2021-12-31 | $154.34M | 56.88% |
| 2020-12-31 | $98.38M | 15.65% |
| 2019-12-31 | $85.07M | 52.83% |
| 2018-12-31 | $55.66M | 44.77% |
| 2017-12-31 | $38.45M | - |
Adaptive Bio generated $178.96M in revenue during NA 2024, up 5.10% compared to the previous quarter, and up 210.36% compared to the same period a year ago.
Adaptive Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $58.88M | 12.27% |
| 2025-03-31 | $52.44M | 10.50% |
| 2024-12-31 | $47.46M | 2.21% |
| 2024-09-30 | $46.44M | 7.51% |
| 2024-06-30 | $43.19M | 3.15% |
| 2024-03-31 | $41.87M | -8.54% |
| 2023-12-31 | $45.78M | 20.74% |
| 2023-09-30 | $37.92M | -22.50% |
| 2023-06-30 | $48.93M | 29.96% |
| 2023-03-31 | $37.65M | -31.80% |
| 2022-12-31 | $55.20M | 15.40% |
| 2022-09-30 | $47.83M | 9.55% |
| 2022-06-30 | $43.66M | 13.05% |
| 2022-03-31 | $38.62M | 1.82% |
| 2021-12-31 | $37.93M | -3.89% |
| 2021-09-30 | $39.47M | 2.50% |
| 2021-06-30 | $38.51M | 0.16% |
| 2021-03-31 | $38.44M | 27.35% |
| 2020-12-31 | $30.18M | 14.78% |
| 2020-09-30 | $26.30M | 25.30% |
| 2020-06-30 | $20.99M | 0.37% |
| 2020-03-31 | $20.91M | -13.63% |
| 2019-12-31 | $24.21M | -7.10% |
| 2019-09-30 | $26.06M | 17.71% |
| 2019-06-30 | $22.14M | 74.78% |
| 2019-03-31 | $12.67M | -26.33% |
| 2018-12-31 | $17.19M | 0.02% |
| 2018-09-30 | $17.19M | 48.58% |
| 2018-06-30 | $11.57M | 19.07% |
| 2018-03-31 | $9.71M | - |
Adaptive Bio generated $58.88M in revenue during Q2 2025, up 12.27% compared to the previous quarter, and up 140.61% compared to the same period a year ago.
Adaptive Bio Revenue Breakdown
Adaptive Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|
| Sequencing Revenue | $78.90M | $41.44M | $43.52M |
| Development Revenue Regulatory Milestones | $10.00M | $2.50M | $2.00M |
| Development Support Revenue | $65.45M | $54.44M | $39.55M |
| Development Revenue | - | $56.94M | $41.55M |
Latest
Adaptive Bio's latest annual revenue breakdown by segment (product or service), as of Dec 21: Sequencing Revenue (51.12%), Development Support Revenue (42.40%), and Development Revenue Regulatory Milestones (6.48%).
Quarterly Revenue by Product
| Product/Service | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicare Revenue | $500.00K | $1.40M | $500.00K | - | - | - | - | - | - | - | - |
| Development Revenue | - | - | - | $23.27M | $17.48M | $15.02M | $13.00M | $11.44M | - | - | - |
| Sequencing Revenue | - | - | - | $15.17M | $12.71M | $11.28M | $7.99M | $9.47M | $13.89M | $11.68M | $11.87M |
| Sequencing Revenue From Coverage Policy | - | - | - | - | - | - | - | - | $500.00K | $300.00K | $300.00K |
| Sequencing Revenue From Test Deliver | - | - | - | - | - | - | - | - | - | $100.00K | $100.00K |
Latest
Adaptive Bio's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: Medicare Revenue (100.00%).
Adaptive Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| GLPG | Galapagos | $239.70M | $62.43M |
| TVTX | Travere Therapeutics | $233.18M | $114.45M |
| ARQT | Arcutis Biotherapeutics | $196.54M | $65.85M |
| ADPT | Adaptive Bio | $178.96M | $58.88M |
| AGIO | Agios Pharmaceuticals | $36.50M | $12.46M |
| IBRX | ImmunityBio | $14.74M | $26.43M |
| MESO | Mesoblast | $7.50M | $1.69M |
| IDYA | IDEAYA Biosciences | $7.00M | - |
| IRON | Disc Medicine | - | - |
| BEAM | Beam Therapeutics | - | - |
| DNLI | Denali Therapeutics | - | - |